Table 1 Baseline characteristics of DE033 and NOR-DMARD patients
CharacteristicAll patientsPatients working at baseline
Mean (95% CI)95% CI*Mean (95% CI)95% CI*
DE033 (n = 486)NOR-DMARD (n = 747)DE033 (n = 158)NOR-DMARD (n = 180)
Disease duration (years)12.3 (11.6 to 13.0)13.0 (12.3 to 13.6)−1.7 to 0.410.5 (9.4 to 11.6)10.7 (9.5 to 11.9)−1.8 to 1.5
Women (%)78.2 (74.5 to 81.9)74.3 (71.2 to 77.4)−8.8 to 10.069.0 (61.7 to 76.3)68.3 (61.5 to 75.2)−9.3 to 10.6
Working at baseline (%)32.5 (28.3 to 36.7)24.1 (21.0 to 27.2)3.3 to 13.5
Age (years)53.7 (52.6 to 54.8)57.0 (56.1 to 58.0)−4.8 to −1.945.3 (43.7 to 46.9)48.1 (46.7 to 49.5)−4.9 to −0.7
C-reactive protein (mg/L)195 (172 to 218)245 (226 to 263)−79 to −21190 (150 to 229)187 (157 to 228)−47 to 52
Erythrocyte sedimentation rate (mm/h)31.4 (29.4 to 33.5)28.7 (27.1 to 30.4)0.1 to 5.327.4 (24.1 to 30.7)20.3 (17.7 to 23.0)2.9 to 11.2
Swollen joint count (28 joints)6.1 (5.6 to 6.6)8.1 (7.7 to 8.5)−2.7 to −1.46.6 (5.6 to 7.5)7.4 (6.6 to 8.2)−2.1 to 0.4
Tender joint count (28 joints)7.0 (6.4 to 7.7)8.2 (7.7 to 8.7)−2.0 to −0.47.0 (5.9 to 8.1)7.0 (6.1 to 7.9)−1.4 to 1.4
DAS284.2 (4.0 to 4.3)4.9 (4.8 to 5.0)−0.9 to −0.64.2 (3.9 to 4.4)4.6 (4.4 to 4.8)−0.7 to −0.2
Patient-rated joint pain (0–100 VAS)33.0 (30.9 to 35.2)50.9 (49.3 to 52.5)−20.5 to −15.331.4 (27.7 to 35.2)44.9 (41.7 to 48.2)−18.4 to −8.6
Patient-rated global disease activity (0–100 VAS)27.3 (25.3 to 29.2)42.5 (41.2 to 43.7)−17.4 to −13.032.2 (28.5 to 35.8)49.4 (46.0 to 52.8)−22.2 to −12.2
Physician-rated global disease activity (0–100 VAS)33.3 (31.2 to 35.4)54.9 (53.2 to 56.5)−24.2 to −18.926.8 (23.5 to 30.1)39.8 (37.3 to 42.2)−17.0 to −9.0
  • *Confidence intervals refer to the difference between the DE033 and NOR-DMARD groups within the category “All patients” or “Patients working at baseline”.

  • DAS28, 28-joint Disease Activity Score; NOR-DMARD, patients receiving disease-modifying antirheumatic drugs from Norway-based longitudinal registry; VAS, visual analogue scale.